GBR 12909 dihydrochloride

Pricing Availability   Qty
Cat.No. 0421 - GBR 12909 dihydrochloride | C28H32F2N2O.2HCl | CAS No. 67469-78-7
Description: Selective DA uptake inhibitor; also σ ligand
Chemical Name: 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride
Purity: ≥98% (HPLC)
Citations (12)
Reviews (1)
Literature (4)

Biological Activity

Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.

Compound Libraries

GBR 12909 dihydrochloride is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 523.49
Formula C28H32F2N2O.2HCl
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 67469-78-7
PubChem ID 104920

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
water 2.62 5 with gentle warming
DMSO 26.17 50

Preparing Stock Solutions

The following data is based on the product molecular weight 523.49. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 3.82 mL 19.1 mL 38.21 mL
2.5 mM 0.76 mL 3.82 mL 7.64 mL
5 mM 0.38 mL 1.91 mL 3.82 mL
25 mM 0.08 mL 0.38 mL 0.76 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:


References are publications that support the biological activity of the product.

Andersen (1989) The DA uptake inhibitor GBR12909: selectivity and molecular mechanism of action. Eur.J.Pharmacol. 166 493 PMID: 2530094

Contreras et al (1990) GBR-12909 and fluspirilene potently inhibited binding of [3H] (+)3-PPP to sigma receptors in rat brain. Life Sci. 47 PL133 PMID: 1980329

Heikkila and Manzino (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of DA uptake. Eur.J.Pharmacol. 103 241 PMID: 6237922

Spealman and Melia (1991) Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J.Pharmacol.Exp.Ther. 258 626 PMID: 1678014

If you know of a relevant reference for GBR 12909 dihydrochloride, please let us know.

View Related Products by Product Action

View all Dopamine Transporter Inhibitors

Keywords: GBR 12909 dihydrochloride, GBR 12909 dihydrochloride supplier, Potent, σ, sigma, ligand, DA, uptake, inhibitors, inhibits, Selective, General, Receptors, DAT, Dopamine, Transporters, Monoamine, Neurotransmitter, GBR12909, dihydrochloride, Sigma-Related, 0421, Tocris Bioscience

12 Citations for GBR 12909 dihydrochloride

Citations are publications that use Tocris products. Selected citations for GBR 12909 dihydrochloride include:

Beerepoot et al (2016) Pharmacological Chaperones of the DA Transporter Rescue DA Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem 291 22053 PMID: 27555326

Hutchinson et al (2012) Differential regulation of MeCP2 phosphorylation in the CNS by DA and serotonin. J Neurosci 37 321 PMID: 21956448

Kim et al (2015) Spinal DArgic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism. J Neurosci 35 6307 PMID: 25904784

Wang et al (2014) Enhanced synthesis and release of DA in transgenic mice with gain-of-function α6* nAChRs. J Neurochem 129 315 PMID: 24266758

Squillace et al (2014) Dysfunctional DArgic neurotransmission in asocial BTBR mice. Transl Psychiatry 4 e427 PMID: 25136890

Koprich et al (2011) Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One 6 e17698 PMID: 21408191

Navaroli et al (2011) The plasma membrane-associated GTPase Rin interacts with the DA transporter and is required for protein kinase C-regulated DA transporter trafficking. J Neurosci 31 13758 PMID: 21957239

Costa et al (2008) Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28 8040 PMID: 18685029

Visanji et al (2008) PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 22 2488 PMID: 18364399

Patel et al (2012) Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS One 7 e41623 PMID: 22911828

Koprich et al (2010) Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pat Mol Neurodegener 5 43 PMID: 21029459

Abdallah et al (2009) Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal DA pathway function. Br J Pharmacol 29 8156 PMID: 19553455

Do you know of a great paper that uses GBR 12909 dihydrochloride from Tocris? Please let us know.

Reviews for GBR 12909 dihydrochloride

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used GBR 12909 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

GBR used as a selective DAT blocker for increasing dopamine release.
By Anonymous on 05/15/2018
Assay Type: Ex Vivo
Species: Mouse

GBR-12909 (300 nM) was used as a DAT blocker in slice voltametry experiments. It's difficult to get into solution. Just use some warming.

PMID: 28115487
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.


Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.